The Hospital Medicines List (HML)

Section H

for Hospital Pharmaceuticals

Update effective 1 April 2014
Contents

Summary of decisions effective 1 April 2014.................................................. 3
Section H changes to Part II ............................................................................. 4
Index............................................................................................................. 7
Summary of decisions
EFFECTIVE 1 APRIL 2014

• Azathioprine (Azamun) tab 50 mg – new listing and addition of HSS
• Azathioprine (Imuprine) tab 50 mg – delisting from 1 June 2014
• Betahistine dihydrochloride (Vergo 16) tab 16 mg – price reduction and addition of HSS
• Cefepime (DBL Cefepime) inj 1 g vial and 2 g vial – HSS suspended 31 March 2014
• Diltiazem hydrochloride (Apo-Diltiazem) cap long-acting 180 mg and 240 mg – HSS suspended 31 March 2014
• Diltiazem hydrochloride (Cardizem CD) cap long-acting 180 mg and 240 mg – new listing
• Imatinib mesilate (Imatinib-AFT) cap 100 mg – new listing and addition of HSS
• Methotrexate (Trexate) tab 2.5 mg and 10 mg – new listing and addition of HSS
• Methotrexate (Methoblastin) tab 2.5 mg and 10 mg – delisting from 1 June 2014
• Oral feed (Ensure (Chocolate)) powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can, 850 g – new listing
• Oral feed (Ensure (Chocolate)) powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can, 900 g – delisting from 1 June 2014
• Oral feed 1.5 kcal/ml (Ensure Plus (Strawberry)) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can – delisting from 1 June 2014
• Pergolide (Permax) tab 0.25 mg and 1 mg – delisting from 1 May 2014
• Prochlorperazine (Antinaus) tab 5 mg – price reduction and addition of HSS
• Rituximab (Mabthera) inj 10 mg per ml, 10 ml and 50 ml vial – amendment to restriction
• Suxamethonium chloride (AstraZeneca) inj 50 mg per ml, 2 ml ampoule – price reduction and addition of HSS
• Trisodium citrate, inj 46.7%, 3 ml syringe – new listing
Section H changes to Part II
Effective 1 April 2014

BLOOD AND BLOOD FORMING ORGANS

30  TRISODIUM CITRATE
    Inj 46.7%, 3 ml syringe

CARDIOVASCULAR SYSTEM

40  DILTIAZEM HYDROCHLORIDE (HSS suspended and new listing)
    Cap long-acting 180 mg
    – 5% DV Feb-13 to 31/03/14 29.15 .......................... 47.67  500  Apo-Diltiazem CD
    – 5% DV Feb-13 to 31/03/14 29.15 .......................... 7.56   30  Cardizem CD
    Cap long-acting 240 mg
    – 5% DV Feb-13 to 31/03/14 29.15 .......................... 63.58  500  Apo-Diltiazem CD
    – 5% DV Feb-13 to 31/03/14 29.15 .......................... 10.22  30  Cardizem CD

INFECTIONS – AGENTS FOR SYSTEMIC USE

66  CEFEPIME (HSS suspended)
    ➔ Inj 1 g vial – 1% DV Oct-12 to 31/03/14 .................. 8.80   1  DBL Cefepime
    ➔ Inj 2 g vial – 1% DV Oct-12 to 31/03/14 .................. 17.60  1  DBL Cefepime

MUSCULOSKELETAL SYSTEM

94  SUXAMETHONIUM CHLORIDE (↓ price and addition of HSS)
    Inj 50 mg per ml, 2 ml ampoule – 1% DV Jun-14 to 2017...... 78.00  50  AstraZeneca

NERVOUS SYSTEM

98  PERGOLIDE (delisting)
    Tab 0.25 mg – 1% DV Sep-11 to 2014 .......................... 48.00  100  Permax
    Tab 1 mg – 1% DV Sep-11 to 2014 ............................ 170.00 100  Permax
    Note – Permax tab 0.25 mg and 1 mg to be delisted from 1 May 2014.

111  BETAHISTINE DIHYDROCHLORIDE (↓ price and addition of HSS)
    Tab 16 mg – 1% DV Jun-14 to 2017 ............................. 4.95   84  Vergo 16

112  PROCHLORPERAZINE (↓ price and addition of HSS)
    Tab 5 mg – 1% DV Jun-14 to 2017 ............................. 9.75  500  Antinaus

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

123  METHOTREXATE
    Tab 2.5 mg – 1% DV Jun-14 to 2015 ............................ 3.82   30  Trexate
    Tab 10 mg – 1% DV Jun-14 to 2015 ............................ 26.25  50  Trexate
    Note – Methoblastin tab 2.5 mg and 10 mg to be delisted from 1 June 2014.
Changes to Section H Part II – effective 1 April 2014 (continued)

129 IMATINIB MESILATE
Cap 100 mg – 1% DV Jul-14 to 2017................................................. 298.90  60 Imatinib-AFT
Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA0643 in Section B of the Pharmaceutical Schedule.

152 AZATHIOPRINE
Tab 50 mg – 1% DV Jun-14 to 2016................................................. 13.22  100 Azamun
Note – Imuprine tab 50 mg to be delisted from 1 June 2014.

149 RITUXIMAB (amendment to restriction)
⇒ Inj 10 mg per ml, 10 ml vial.................................................. 1,075.50  2 Mabthera
⇒ Inj 10 mg per ml, 50 ml vial.................................................. 2,688.30  1 Mabthera
Initiation – ANCA associated vasculitis
Rheumatologist or nephrologist
Limited to 4 weeks’ treatment
All of the following:
1 Patient has been diagnosed with ANCA associated vasculitis*; and
2 Either:
   2.1 Patient does not have MPO-ANCA positive vasculitis*; or
   2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis*; and
3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
4 Any of the following:
   4.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence of disease after at least 3 months; or
   4.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or
   4.3 Cyclophosphamide and methotrexate are contraindicated; or
   4.4 Patient is a female of child-bearing potential; or
   4.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.
Note: Indications marked with * are Unapproved Indications.

Continuation – ANCA associated vasculitis
Rheumatologist or nephrologist
Limited to 4 weeks’ treatment
All of the following:
1 Patient has been diagnosed with ANCA associated vasculitis*; and
2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3 The total rituximab dose would not exceed the equivalent

SPECIAL FOODS

195 ORAL FEED 1.5 KCAL/ML (delisting)
⇒ Liquid 5.5 g protein, 21.1 g carbohydrate
   and 4.81 g fat per 100 ml, can............................................. 1.33  237 ml Ensure Plus (Strawberry)
Note – Ensure Plus (Strawberry) to be delisted from 1 June 2014.
<table>
<thead>
<tr>
<th>Price (ex man. Excl. GST) $</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Changes to Section H Part II – effective 1 April 2014 (continued)**

195  ORAL FEED

- Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can .............................. 13.00 850 g Ensure (Chocolate)

Note – Ensure (Chocolate) in the 900 g pack size to be delisted from 1 June 2014.
# Index
**Pharmaceuticals and brands**

<table>
<thead>
<tr>
<th>A</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antinaus</td>
<td>4</td>
</tr>
<tr>
<td>Apo-Diltiazem CD</td>
<td>4</td>
</tr>
<tr>
<td>Azamun</td>
<td>5</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>5</td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Betahistine dihydrochloride</td>
<td>4</td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Cardizem CD</td>
<td>4</td>
</tr>
<tr>
<td>Cefepime</td>
<td>4</td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>DBL Cefepime</td>
<td>4</td>
</tr>
<tr>
<td>Diltiazem hydrochloride</td>
<td>4</td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>Ensure (Chocolate)</td>
<td>6</td>
</tr>
<tr>
<td>Ensure Plus (Strawberry)</td>
<td>5</td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>Imatinib-AFT</td>
<td>5</td>
</tr>
<tr>
<td>Imatinib mesilate</td>
<td>5</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Mabthera</td>
<td>5</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>4</td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>Oral feed</td>
<td>6</td>
</tr>
<tr>
<td>Oral feed 1.5 kcal/ml</td>
<td>5</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Pergolide</td>
<td>4</td>
</tr>
<tr>
<td>Permax</td>
<td>4</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>4</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>5</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Suxamethonium chloride</td>
<td>4</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Trexate</td>
<td>4</td>
</tr>
<tr>
<td>Trisodium citrate</td>
<td>4</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Vergo 16</td>
<td>4</td>
</tr>
</tbody>
</table>